Xencor Inc. (XNCR)

NASDAQ: XNCR · Real-Time Price · USD

11.30

0.44 (4.05%)

At close: May 02, 2025, 3:59 PM

11.26

-0.40%

After-hours: May 02, 2025, 04:05 PM EDT

4.05% (1D)

Bid	8.4
Market Cap	804.37M
Revenue (ttm)	110.49M
Net Income (ttm)	-232.62M
EPS (ttm)	-3.58
PE Ratio (ttm)	-3.16
Forward PE	-4.66
Analyst	Buy

Ask	12.33
Volume	801,317
Avg. Volume (20D)	754,832
Open	11.07
Previous Close	10.86
Day's Range	10.86 - 11.70
52-Week Range	7.16 - 27.24
Beta	0.90

About XNCR

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with r...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 3, 2013

Employees 250

Stock Exchange NASDAQ

Ticker Symbol XNCR

Website https://www.xencor.com

Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for XNCR stock is "Buy." The 12-month stock price forecast is $34, which is an increase of 200.75% from the latest price.

Stock Forecasts

Next Earnings Release

Xencor Inc. is scheduled to release its earnings on May 16, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

7 months ago

+10.45%

Xencor shares are trading higher. The company pric... Unlock content with Pro Subscription

7 months ago

+22.93%

Xencor shares are trading higher after the company announced four new XmAb programs in development for the treatment of patients with autoimmune diseases and provided updates from dose-escalation studies evaluating its first-in-class oncology programs.

News

1 day ago · zacks.com

Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago · zacks.com

Xencor (XNCR) Upgraded to Buy: Here's Why

Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · zacks.com

Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

Xencor (XNCR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.31 per share a year ago.

2 months ago · businesswire.com

Xencor Reports Fourth Quarter and Full Year 2024 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re...